Effects of a domain-selective ACE inhibitor in a mouse model of chronic angiotensin II-dependent hypertension

Clinical Science

Volumn 127, Issue 1, 2014, Pages 57-63

  Burger, Dylan ^a   Reudelhuber, Timothy L ^b   Mahajan, Aman ^c   Chibale, Kelly ^c   Sturrock, Edward D ^c   Touyz, Rhian M ^a,d  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Angiotensin 1 converting enzyme (ACE); Bradykinin; Hypertension; Lisinopril tryptophan (lisW S)

Indexed keywords

ANGIOTENSIN II; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; LISINOPRIL TRYPTOPHAN; RENIN; TRYPTOPHAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; KIDNEY HYPERTROPHY; LIVER; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; SPHYGMOMANOMETRY; SYSTOLIC BLOOD PRESSURE; TELEMETRY;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BRADYKININ; CARDIOMEGALY; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HYPERTENSION; HYPERTROPHY; KIDNEY; LISINOPRIL; MICE; MICE, TRANSGENIC;

EID: 84896033419     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20130808     Document Type: Article

References (28)

1. Nguyen Dinh Cat, A., Montezano, A. C., Burger, D. and Touyz, R. M. (2013) Angiotensin II, NADPH oxidase, and redox signaling in the vasculature. Antioxid. Redox Signal. 19, 1110-1120
2. Savoia, C., Burger, D., Nishigaki, N., Montezano, A. and Touyz, R. M. (2011) Angiotensin II and the vascular phenotype in hypertension. Expert Rev. Mol. Med. 13, e11
3. Bernstein, K. E., Ong, F. S., Blackwell, W. L., Shah, K. H., Giani, J. F., Gonzalez-Villalobos, R. A., Shen, X. Z., Fuchs, S. and Touyz, R. M. (2013) A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol. Rev. 65, 1-46
4. Bernstein, K. E., Martin, B. M., Edwards, A. S. and Bernstein, E. A. (1989) Mouse angiotensin-converting enzyme is a protein composed of two homologous domains. J. Biol. Chem. 264, 11945-11951
5. Soubrier, F., Alhenc-Gelas, F., Hubert, C., Allegrini, J., John, M., Tregear, G. and Corvol, P. (1988) Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc. Natl. Acad. Sci. U.S.A. 85, 9386-9390
6. Wei, L., Alhenc-Gelas, F., Corvol, P. and Clauser, E. (1991) The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J. Biol. Chem. 266, 9002-9008
7. Wei, L., Clauser, E., Alhenc-Gelas, F. and Corvol, P. (1992) The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J. Biol. Chem. 267, 13398-13405
8. Gonzalez-Villalobos, R. A., Shen, X. Z., Bernstein, E. A., Janjulia, T., Taylor, B., Giani, J. F., Blackwell, W. L., Shah, K. H., Shi, P. D., Fuchs, S. and Bernstein, K. E. (2013) Rediscovering ACE: novel insights into the many roles of the angiotensin-converting enzyme. J. Mol. Med. 91, 1143-1154
9. Jaspard, E., Wei, L. and Alhenc-Gelas, F. (1993) Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J. Biol. Chem. 268, 9496-9503
10. Semple, P. F. (1995) Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors. J. Hypertens. Suppl. 13, S17-S21
11. Dicpinigaitis, P. V. (2006) Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 129, 169S-173S
12. Junot, C., Gonzales, M. F., Ezan, E., Cotton, J., Vazeux, G., Michaud, A., Azizi, M., Vassiliou, S., Yiotakis, A., Corvol, P. and Dive, V. (2001) RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis. J. Pharmacol. Exp. Ther. 297, 606-611
13. Watermeyer, J. M., Kroger, W. L., O'Neill, H. G., Sewell, B. T. and Sturrock, E. D. (2010) Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril. Biochem. J. 428, 67-74
14. Nchinda, A. T., Chibale, K., Redelinghuys, P. and Sturrock, E. D. (2006) Synthesis and molecular modeling of a lisinopril-tryptophan analogue inhibitor of angiotensin I-converting enzyme. Bioorg. Med. Chem. Lett. 16, 4616-4619
15. Prescott, G., Silversides, D. W., Chiu, S. M. and Reudelhuber, T. L. (2000) Contribution of circulating renin to local synthesis of angiotensin peptides in the heart. Physiol. Genomics 4, 67-73
16. Touyz, R. M., Mercure, C., He, Y., Javeshghani, D., Yao, G., Callera, G. E., Yogi, A., Lochard, N. and Reudelhuber, T. L. (2005) Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NADPH oxidase. Hypertension 45, 530-537
17. Yogi, A., Mercure, C., Touyz, J., Callera, G. E., Montezano, A. C., Aranha, A. B., Tostes, R. C., Reudelhuber, T. and Touyz, R. M. (2008) Renal redox-sensitive signaling, but not blood pressure, is attenuated by Nox1 knockout in angiotensin II-dependent chronic hypertension. Hypertension 51, 500-506
18. Corder, R. (2000) Effect of lisinopril on tissue levels of neuropeptide Y in normotensive and spontaneously hypertensive rats. J. Hum. Hypertens. 14, 381-384
19. Campbell, D. J., Alexiou, T., Xiao, H. D., Fuchs, S., McKinley, M. J., Corvol, P. and Bernstein, K. E. (2004) Effect of reduced angiotensin-converting enzyme gene expression and angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptide levels in mice. Hypertension 43, 854-859
20. Burger, D., Montezano, A. C., Nishigaki, N., He, Y., Carter, A. and Touyz, R. M. (2011) Endothelial microparticle formation by angiotensin II is mediated via Ang II receptor type I/NADPH oxidase/Rho kinase pathways targeted to lipid rafts. Arterioscler. Thromb. Vasc. Biol. 31, 1898-1907
21. Carlson, S. H. and Wyss, J. M. (2000) Long-term telemetric recording of arterial pressure and heart rate in mice fed basal and high NaCl diets. Hypertension 35, E1-E5
22. Javeshghani, D., Touyz, R. M., Sairam, M. R., Virdis, A., Neves, M. F. and Schiffrin, E. L. (2003) Attenuated responses to angiotensin II in follitropin receptor knockout mice, a model of menopause-associated hypertension. Hypertension 42, 761-767
23. Van Vliet, B. N., McGuire, J., Chafe, L., Leonard, A., Joshi, A. and Montani, J.-P. (2006) Phenotyping the level of blood pressure by telemetry in mice. Clin. Exp. Pharmacol. Physiol. 33, 1007-1015
24. Fuchs, S., Xiao, H. D., Hubert, C., Michaud, A., Campbell, D. J., Adams, J. W., Capecchi, M. R., Corvol, P. and Bernstein, K. E. (2008) Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension 51, 267-274
25. Fuchs, S., Xiao, H. D., Cole, J. M., Adams, J. W., Frenzel, K., Michaud, A., Zhao, H., Keshelava, G., Capecchi, M. R., Corvol, P. and Bernstein, K. E. (2004) Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice. J. Biol. Chem. 279, 15946-15953
26. Caldeira, D., David, C. and Sampaio, C. (2012) Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis. Am. J. Cardiovasc. Drugs 12, 263-277
27. Haulica, I., Bild, W. and Serban, D. N. (2005) Angiotensin peptides and their pleiotropic actions. J. Renin Angiotensin Aldosterone Syst. 6, 121-131
28. Juillerat-Jeanneret, L. (1993) Modulation of proteolytic activity in tissues following chronic inhibition of angiotensin-converting enzyme. Biochem. Pharmacol. 45, 1447-1454